Abstract: This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12.

Abstract: The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

Abstract: This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition is substantially free of surfactant having an HLB greater than about 12.

Abstract: Microencapsulation methods are provided using encapsulant, fiber or film forming compositions of a cross-linkable anionic polymer, a multivalent cation salt, a chelating agent, and a volatile base. During the formation of this composition, the generally acidic chelating agent is titrated with a volatile base to an elevated pH to improve ion-binding capability. Multivalent cations are sequestered in cation-chelate complexes. Cross-linkable polymers in this solution will remain freely dissolved until some disruption of equilibrium induces the release of the free multivalent cations from the cation-chelate complex. Vaporization of the volatile base drops the pH of the solution causing the cation-chelate complexes to dissociate and liberate multivalent cations that associate with the anionic polymer to form a cross-linked matrix. During spray-drying, the formation of a wet particle, polymer cross-linking, and particle drying occur nearly simultaneously.

Abstract: This invention relates generally to water-insoluble but water-swellable and deformable crosslinked PEGylated microgel particles of proteins and protein-based macromolecules that are pseudoplastic (shear thinning) and flow in aqueous media under shear and which can be injected or made to flow, wherein said microgel particles can reform as a cluster of microgel particles when shearing forces are removed. The microgel particles function as a matrix to support cell growth, viability, and proliferation.

Abstract: There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.

Abstract: The disclosed and/or claimed inventive concept(s) provides a complex of at least one halogen and a compound comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties. The disclosed and/or claimed inventive concept(s) further provides compositions comprising the complexes and applications thereof in various industrial areas including personal care, home care, pharmaceuticals, antimicrobials, disinfectants, biocides, germicides, and coatings.

Abstract: Provided are methods of producing mono- and di-pegylated IL-10.

Abstract: The present application relates to a nondetergent cosmetic composition comprising at least one alkoxysilane comprising at least one basic functional group and at least one microbial gum. The present disclosure also relates to the use, for the treatment of keratin materials, such as the hair, for example, damaged, curly, dry or fine hair, of this composition, and also to a method of hair shaping comprising the application of said composition to the hair.

Abstract: The present disclosure is directed to alcohol-based anti-adherent compositions that do not adhere to or attract Gram-negative and Gram-positive bacteria once it is applied to a surface and dried. The composition may include as anti-adherent agents, hydrophilic film-formers such as cellulosics, gums, acrylates, nonionic polymers, and anionic polymers. Examples of anti-adherent agents include Hydroxypropyl methylcellulose, Cellulose gum, Acacia Senegal Gum; Polyacrylate Crosspolymer-11, VP/Dimethyl-aminoethylmethacrylate/Polycarbamyl Polyglycol Ester; Acrylates/Vinyl Neodecanoate Crosspolymer, hydroxypropyl methylcellulose, Hydroxypropylcellulose, Methylcellulose, Propylene Glycol Alginate, Polyacrylate Crosspolymer-6, VP/Polycarbamyl Polyglycol Ester, Acrylates/Steareth-20 Methacrylate Copolymer; Acrylates Copolymer, and any combination thereof. The anti-adherent may be applied to surfaces using a vehicle such as a wipe.

Abstract: The present invention relates to esterified polysaccharide osmotics, use of same, processes for synthesis of same as well as compositions containing same.

Abstract: An intraocular lens insertion apparatus includes a hollow tube having an interior wall defining a hollow space through which an intraocular lens may be passed from the open space into an eye. A lubricity enhancing component is covalently bonded to the hollow tube at the interior wall in an amount effective to facilitate the passage of the intraocular lens through the hollow space. The lubricity enhancing component includes a substituent component effective to reduce hydrolysis of said lubricity enhancing component relative to an identical lubricity enhancing component without the substituent component.

Abstract: This invention pertains to a polymeric composition and an antimicrobial composition, each comprising a superabsorbent polymer (SAP), such as used in diapers and sanitary napkins, and peroxide. The superabsorbent material can be made by the process of treating a preformed SAP, such as a crosslinked polyacrylate salt, with a treatment solution comprising hydrogen peroxide dissolved in water, followed by drying. The resulting superabsorbent material has strong antimicrobial activity. Optionally, the treatment solution may also contain a metal salt, including those of zinc, zirconium, and magnesium.

Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.

Abstract: A block copolymer comprising a methoxyethyl methacrylate (MOEMA) midblock is provided for forming a coating a medical device for controlled release of a bioactive agent.

Abstract: The present invention relates to a new class of cationic polymers that self-assemble with a pH-sensitive dissolution switch, and their uses to deliver molecules of interest to a cell. The present invention also relates to compositions comprising said cationic polymers non-covalently associated with a molecule of interest, in particular with a siRNA.

Abstract: A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) and further wherein, when said material is in an environment capable of transporting H+ ions, said solid buffer is adapted to cause the death of at least one target cell within or in contact with said environment. A selectively permeable barrier layer may be provided covering the solid buffer.

Abstract: The present invention provides a wound dressing comprising a tessellated water-soluble molding matrix comprised of a polymer selected from the group consisting of polyvinyl alcohol, gelatin, and mixtures thereof and a 1,1-disubstituted ethylene monomer. The present invention further provides methods of using the wound dressing and kits containing the wound dressing.

Abstract: A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel.

Abstract: A method of in-situ adhering comprising providing pre-gel that comprises a mixture of at least one phenol-based compound and at least one water miscible polymer selected from at least one of a naturally existing form of a carbohydrate, a synthetically prepared form of carbohydrate and a salt of an anionic polysaccharide; spreading a layer of the pre-gel onto a first surface; adding a solid support, comprising at least one cross linking agent capable of interacting with the water miscible polymer to the pre-gel; and allowing the pre-gel to cure and adhere onto the first surface.

Abstract: A composition-of-matter is provided as well as pharmaceutical compositions and methods of using same. The composition of matter includes least one active moiety surrounded by a scaffold configured for enabling selective influx of an agent capable of interacting with the at least one active moiety.

Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.

Abstract: Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates.

Abstract: The present invention relates to immunogenic complexes formed between polyanionic carbomers and Env polypeptides. Uses of the immunogenic complexes in applications including inducing an immune response and immunization generally are described. Methods of forming and manufacture of the immunogenic complexes are also described. The present invention also relates to immunogenic compositions including low viscosity, polyanionic carbomers and Env polypeptides. Uses of such immunogenic compositions in applications including inducing an immune response and immunization generally are described. Methods of manufacture of such immunogenic compositions are also described.

Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.

Abstract: The invention concerns methods of treating blood, blood product, or physiologic fluid to provide at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; said method comprising contacting said blood, blood product or physiologic fluid with a sorbent, said sorbent being primarily in a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of at least one of (1) zwitterionic moieties and (2) oligo(ethylene glycol) moieties attached to the surface of said cross-linked polymeric material.

Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

Abstract: The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: Novel, crosslinked polymers using biomass derived materials, such as aldaric acids and derivatives, are provided. The polymers can be used as hydrogels and in antimicrobial compositions.

Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.

Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.

Abstract: Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.

Abstract: Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed.

Abstract: A rotaxane consisting of a cucurbituril and an uncharged guest molecule, having low or null affinity therebetween is provided as well as processes for providing the same. Various uses as energy converters (“frictionless” molecular motors), biochips and biosensors using the same are also provided.

Abstract: A novel class of Cylic Acetal biomaterials (CABs) based on a cyclic acetal unit is disclosed and claimed by Applicants. Two novel biomaterials suitable for use in a variety of biological applications including in the orthopedic field for joint and cartilage replacement and/or repair, and bone cement. The biomaterials are comprised of either a network of monomers of 5-ethyl-5-(hydroxymethyl)-?,?-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) and a hydrogel comprised of EHD and poly(ethylene glycol) diacrylate (PEG-EHD).

Abstract: A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials.

Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.

Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.

Abstract: Provided are methods of producing a mixture of mono- and di-pegylated IL-10.

Abstract: Particles and related methods are disclosed.

Abstract: The present invention relates to degradable polyacetal polymers having a C(O)—(CH2CH2O)n—R5 or a saccharide attached to amine radical of the backbone of the polymer, their polymer-active agent conjugates and their preparation processes, to compositions, and hydrogels containing them, as well as their use in therapy, diagnostic imaging and cosmetics.

Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.

Abstract: Provided herein is an anhydrous cosmetic composition comprising at least one organic structuring agent, at least one modified starch, at least one wood meal, at least one surfactant, and at least one anhydrous liquid phase. Also provided is a method for cleansing and/or conditioning keratin materials, comprising applying at least one of the anhydrous cosmetic compositions to the keratin materials.

Abstract: The present invention is directed to medical devices and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.

Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

Abstract: An antifouling film is coated on a base, and contains a binder component, conductive particles, and a fluororesin. The conductive particles are bound together by the binder component; the binder component is closely bound to the base; and the antifouling film has a comprising the conductive particles of which surfaces are covered with the fluororesin.

Abstract: The present invention relates to organic polymeric photon up-conversion nanoparticles for biological applications, such as labeling and/or detection of cells, biological (macro-) molecules or other analytes, as well as for sensing temperature, pressure, oxygen and other substances that influence the up-conversion process. It further relates to organic photon up-conversion nanoparticles for singlet oxygen generation and the treatment of diseases, such as cancer.

Abstract: The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.